louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05506098: Investigating STAT3 as a Driver of Pathology in Periodontitis
Official title: Investigating STAT3 as a Driver of Pathology and Potential Therapeutic Target in Periodontitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Periodontitis
Keywords: periodontitis, STAT3
Lead sponsor: University of Chile
Sponsor class: OTHER
First posted: 2022-08-18
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female and male adults living in Santiago, Chile.

Brief summary: Periodontitis is a prevalent inflammatory condition that destroys tooth-supporting structures. This condition is associated with pro-inflammatory mediators that utilize STAT3 as an activator of specific genes related to inflammation and tissue destruction. STAT3 has not been studied in the context of periodontitis in humans. We propose that STAT3 is associated with periodontitis. This knowledge might help to further our understanding of periodontitis pathology


Eligibility criteria: Inclusion Criteria:

* 18-year-old, in good general health, and had no significant medical history.
* no history of diabetes or other diseases different than periodontitis.

Exclusion Criteria:

* Pregnancy and lactation
* Use of antibiotics, immunosuppressive agents, or probiotics within 3 months.

Primary outcomes:
measure: STAT3 detection in gingival tissues
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Faculty of Dentistry, University of Chile
Study officials:
References:
Clinical trial NCT06153498: PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function
Official title: A Randomized Study of the PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Mechanically Ventilated Patients
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
Collaborators: name: Yichang Humanwell Pharmaceutical Co., Ltd., China
First posted: 2023-12-01
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Pharmacokinetic/pharmacodynamic profiles of remazolam besylate were compared in patients with impaired and normal renal function in the ICU, and safety was assessed by recording hemodynamic parameters and adverse events.


Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) ≥18 and ≤ 30 kg/m2
* Being Intubated and mechanically ventilated ≤48 hours before enrollment and expected to be on a ventilator for at least 6 hours
* Requirement for light to moderate sedation (a Richmond agitation-sedation scale score of -2 to 1) Patients with impaired renal function were defined as having a glomerular filtration rate of 30 to 89 ml/min/1.73m2. Patients with normal renal function were defined as having a glomerular filtration rate of 90 to 120 ml/min/1.73m2

Exclusion Criteria:

* Refusal to be included
* Allergy or unsuitability to any composition of study drugs or remifentanil
* Living expectancy less than 48 hours
* Myasthenia gravis
* Status asthmaticus
* Abdominal compartment syndrome
* Serious hepatic dysfunction (CTP 10-15);
* Chronic kidney disease with glomerular filtration rate (GFR) \< 29 ml/ min/1.73m2
* Mean blood pressure less than 65 mm Hg or the need for a continuous infusion of norepinephrine at ≥0.5 ug/kg/min to maintain Mean blood pressure ≥ 65 mm Hg
* Possible requirement for surgery or bedside tracheostomy in 24 hours
* Possible requirement for renal replacement therapy in 24 hours
* Acute severe neurological disorder and any other condition interfering with sedation assessment
* Abuse of controlled substances or alcohol
* Pregnancy or lactation

Primary outcomes:
measure: Cmax
timeFrame: Within 24 hours while receiving the study drug
measure: The area under the plasma drug concentration-time curve
timeFrame: Within 24 hours while receiving the study drug
measure: t1/2
timeFrame: Within 24 hours while receiving the study drug
Secondary outcomes:
measure: The percentage of time in the target sedation range without rescue sedation
timeFrame: Within 24 hours while receiving the study drug
measure: The number and severity of treatment emergent adverse events (TEAEs)
timeFrame: Within 24 hours while receiving the study drug
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Wuhan Union Hospital
state: Hubei
Study officials:
References:
Clinical trial NCT06323798: Diffusion Weighted MRI Enables Differential Diagnosis Between Pyocele and Mucocele
Official title: Diffusion Weighted MRI Enables Differential Diagnosis Between Pyocele and Mucocele
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Pyocele; Sinus
Keywords: sinus, pyocele, mri
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2024-03-21
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with paranasal MRI

Brief summary: Diffusion MRI should allow for differentation of pus and simple retention in the paranasal sinuses, but this remained to be determined

Detailed description: On the basis of the apparent diffusion coefficient, the content of a para nasal sinus could be defined as simple mucus or pus. This differentiation is very important for the clinician for prompt treatment. The aim of this study is to retrospectively measure this coefficient and to correlate it to clinica data.

Eligibility criteria: Inclusion Criteria:

* paranasal sinus MRI with a diffusion weighted sequence

Exclusion Criteria:

* no clinical examination available
* no bateriologic sample available

Primary outcomes:
measure: apparent diffusion coefficient
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: CHRU de Nancy
name: romain gillet, md
role: PRINCIPAL_INVESTIGATOR
References:
citation: Radulesco T, Scemama U, Mancini J, Moulin G, Dessi P, Michel J, Varoquaux A. Role of diffusion-weighted imaging in the discrimination of purulent intrasinusal content: A retrospective study. Clin Otolaryngol. 2019 Sep;44(5):762-769. doi: 10.1111/coa.13388. Epub 2019 Jul 23.
Clinical trial NCT00894998: Efficacy and Safety of Sodium Heparin in Patients (Cristália)
Official title: Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Cardiac Surgery
Keywords: heparin cardiac surgery
Lead sponsor: Azidus Brasil
Sponsor class: INDUSTRY
First posted: 2009-05-07
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of this study is to verify, through a randomized, single-blind, multicentre, parallel and comparative study, the effectiveness of heparin sodium of porcine origin in patients undergoing heart surgery at that require the aid of cardiopulmonary bypass, through the control of hemostasis during and after surgery, based on the strengths of markers of coagulation TCA, TTPA, Anti-Xa, heparin bioavailable and loss of excessive blood (bleeding) at the end of the surgery.


Eligibility criteria: Inclusion Criteria:

* Patients who agree with all aspects of the study and sign the FICT;
* Patients of both sexes;
* Patients aged above 18 years;
* Patients with cardiac surgery and requiring movement; AND
* Extracorporeal.

Exclusion Criteria:

* Patients with hematological disorders that compromise the surgical changes (eg myeloproliferative syndromes, anemia Hb \<11.0 g / dL,
* Platelets \< 150,000 mm3);
* Patients with disorders of hemostasis (INR\> 1.40) (rTTPA\> 1.40);
* Patients with renal dysfunction (creatinine\> 1.50);
* Patients with deep hyperthermia;
* Liver disease (AST and ALT\> 2 times that of the reference value);
* Patients with a history of allergy to heparin or protamine;
* Patients with history of heparin-induced thrombocytopenia;
* Tables infection (eg endocarditis, infection of immune human (HIV), hepatitis B and C, septicemia and pneumonia);
* Reoperations;
* Use of antiplatelet (clopidogrel and ticlopidine) for less than 7 days;
* Use of acetylsalicylic acid is less than 5 days;
* Use of low molecular weight heparin for less than 24 hours; OR
* Use of non-fractioned heparin for less than 12 hours.

Primary outcomes:
measure: Comparison of TTPA, Anti-Xa and ACT
timeFrame: Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative
measure: Comparison of bleeding
timeFrame: Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative
Secondary outcomes:
measure: Adverse reactions
timeFrame: Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative
Other outcomes:
Locations:
city: Valinhos
country: Brazil
facility: LAL Clinica Pesquisa e Desenvolvimento Ltda
state: São Paulo
Study officials:
affiliation: LAL Clinical Reseach e Development Ltda
name: Alexandre Frederico, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03182998: Decision Aids to Improve Knowledge in Patients With Prostate Cancer
Official title: Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Institute on Minority Health and Health Disparities (NIMHD)
First posted: 2017-06-09
Enrollment: 103
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This randomized phase III trial studies how well decision aids work in improving knowledge in patients with prostate cancer. Decision aids may improve patients' knowledge of their condition and options for treatment, and may also help when talking with their doctor.


Eligibility criteria: Inclusion Criteria:

* Patients must have prostate biopsy within 4 months prior to registration showing newly diagnosed prostate cancer, stage T1-3N0M0; in addition, patients must have: Gleason score 6-10
* Prostate-specific antigen (PSA) \< 50 ng/mL
* Patients who have had a history of non-cutaneous malignancy in the previous 5 years are not eligible; exception: patients with history of non-melanoma skin cancer are eligible
* Scheduled prostate cancer consultation to be the first consultation after diagnosis (i.e. not a second-opinion or a consultation following previous discussions of treatment options)
* Patients may not be concurrently enrolled to another clinical trial for the treatment of cancer; co-enrollment to biospecimen studies is allowed
* Patients with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) are not eligible for this study
* Patients must be able to read and comprehend English; non-English-speaking patients may participate so long as an interpreter (e.g., family member, clinic staff, etc.) is present for consent, for the decision aid administration, and gathering of baseline and follow-up measures

Primary outcomes:
measure: Knowledge Assessed by Prostate Cancer Treatment Questionnaire
timeFrame: 12 months
Secondary outcomes:
measure: Decisional Quality as Measured by Decisional Regret Scale
timeFrame: 12 months
measure: Quality of Life Assessed by Questionnaire
timeFrame: 12 months
measure: Utilization as Determined by Chart Review
timeFrame: 12 months
Other outcomes:
Locations:
city: Anchorage
country: United States
facility: Alaska Native Tribal Health Consortium
state: Alaska
city: Scottsdale
country: United States
facility: Mayo Clinic
state: Arizona
city: Cleveland
country: United States
facility: University Hospitals Case Medical Center
state: Ohio
city: Cleveland
country: United States
facility: Metrohealth Medical Center Urology Institute
state: Ohio
city: Rapid City
country: United States
facility: Regional Health
state: South Dakota
Study officials:
affiliation: Mayo Clinic
name: Jon C. Tilburt, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03741998: Nasopharyngeal Airway Facilitate Transnasal Humidified Rapid Insufflation Ventilatory Exchange
Official title: Nasopharyngeal Airway Facilitate Transnasal Humidified Rapid Insufflation Ventilatory Exchange
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypoxia
Hypercapnia
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2018-11-15
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: For performing transnasal humidified rapid insufflation ventilatory exchange (THRIVE), jaw-thrust maneuver have to maintain to make sure the airway open and the CO2 clearance during apnoea. The objective of present study is to prove that nasopharyngeal airway facilitate THRIVE and no need jaw-thrust maneuver and maintain the similar PO2 and PCO2 during apnoea.


Eligibility criteria: Inclusion Criteria:

* Signed informed consent.
* Undergoing surgery with general anaesthesia.
* Adult, \>18 years old.
* American Society of Anesthesiology classification I-II.

Exclusion Criteria:

* Coagulation disorders or a tendency of nose bleeding
* An episode/exacerbation of congestive heart failure (CHF) that requires a change in medication, diet or hospitalization from any cause in the last 6 months
* Severe aortic stenosis or mitral stenosis;
* Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months;
* Acute myocardial infarction in the last 6 months;
* Acute arrhythmia (including both tachycardia and bradycardia) with hemodynamic instability;
* Diagnosed COPD or current other acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy);
* Increased intracranial pressure;
* ASA \>II;
* Mouth, nose, or throat infection;
* Fever, defined as core body temperature \> 37.5°C;
* Pregnancy, breastfeeding or positive pregnancy test;
* Emergency procedure.
* Patient with known or suspected difficult airway

Primary outcomes:
measure: The partial pressure of carbon dioxide (pCO2)
timeFrame: From start to end of THRIVE(20 minutes)
measure: The partial pressure of oxygen(PO2)
timeFrame: From start to end of THRIVE(20 minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Renji Hospital
state: Shanghai
Study officials:
affiliation: Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
name: Diansan Su, Dr.
role: STUDY_DIRECTOR
References:
citation: Chen L, Yang L, Tian W, Zhang X, Zhao Y, Huang L, Tian J, Zhang J, Wu J, Yu W, Su D. Transnasal Humidified Rapid Insufflation Ventilatory Exchange With Nasopharyngeal Airway Facilitates Apneic Oxygenation: A Randomized Clinical Noninferiority Trial. Front Med (Lausanne). 2020 Nov 27;7:577891. doi: 10.3389/fmed.2020.577891. eCollection 2020.
Clinical trial NCT06451198: IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Official title: IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Coronary Artery Disease
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2024-06-11
Enrollment: 2846
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and safety of indobufen-based dual antiplatelet therapy (DAPT) (indobufen 100mg bid plus ticagrelor 90mg bid) or conventional DAPT (aspirin 100mg qd plus ticagrelor 90mg bid) in acute coronary syndrome (ACS) patients aged over 70 years old undergoing coronary drug-eluting stent (DES) implantation.


Eligibility criteria: Inclusion Criteria:

* Age over 70 years old
* Diagnosed with acute coronary syndrome (unstable angina/ non-ST elevation myocardial infarction/ ST elevation myocardial infarction)
* Treated with at least 1 DES implanted in the coronary lesion
* Receiving dual antiplatelet therapy (aspirin plus ticagrelor)
* Agree to attend the trial

Exclusion Criteria:

* Elective surgical procedure planned within 12 months
* Life expectancy ≤1 year
* Known allergy or intolerance to aspirin, ticagrelor or nonsteroidal anti-inflammatory drugs (NSAIDs)
* History of cerebral hemorrhage
* History of stroke in six months
* Active bleeding
* Known relevant hematological deviations
* Known, clinically important thrombocytopenia (i.e., \<100\*10\^9/L) or anemia (i.e., \<90g/L)
* Active cancer
* Concomitant use of oral anticoagulants
* Active participation in another clinical study
* Other situations in which the investigator considers unsuitable to attend the study

Primary outcomes:
measure: net adverse clinical events (NACEs)
timeFrame: 1-year
Secondary outcomes:
measure: a composite of CV death, nonfatal MI, ischemic stroke, definite or probable ST
timeFrame: 1-year
measure: BARC criteria type 2, 3 or 5 bleeding events
timeFrame: 1-year
measure: a composite endpoint of CV death, nonfatal MI, ischemic stroke, definite or probable ST, or BARC criteria type 3 or 5 bleeding
timeFrame: 1-year
measure: all-cause mortality
timeFrame: 1-year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03379298: Children's Health Study Diet and Air Pollution
Official title: Regional and Traffic-related Air Pollutants Are Associated With Consumption of a High Fat Diet Among Adolescents
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diet Habit
Pollution; Exposure
Child Obesity
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2017-12-20
Enrollment: 3142
Sex: ALL
Minimum age (years): 13
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children from 12 Southern California communities were enrolled into the study in 4th and 7th grades (1993-1994) and were followed annually until high school graduation (1998-2001).

Brief summary: This study is built upon the existing data in the Children's Health Study to examine the longitudinal association between childhood exposure to air pollutants and changes in diet among adolescents.


Eligibility criteria: Inclusion Criteria:

* children of 4th and 7th grades were enrolled from 12 Southern California communities

Exclusion Criteria:

* extreme mean caloric intake (\>5000 or \< 500 kcal/day) or no demographic information

Primary outcomes:
measure: Dietary behavior
timeFrame: one year before visit date
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Chen Z, Herting MM, Chatzi L, Belcher BR, Alderete TL, McConnell R, Gilliland FD. Regional and traffic-related air pollutants are associated with higher consumption of fast food and trans fat among adolescents. Am J Clin Nutr. 2019 Jan 1;109(1):99-108. doi: 10.1093/ajcn/nqy232.
Clinical trial NCT07001098: Amino Acids for Cardiac Surgery Associated AKI
Official title: Amino Acids for the Infant at Risk for Acute Kidney Injury After Cardiac Surgery: A Pilot Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Acute Kidney Injury
Keywords: cardiac surgery
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2025-06-03
Enrollment: 30
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the feasibility of amino acid infusions in pediatric cardiac surgery patients.


Eligibility criteria: Inclusion Criteria:

* Undergoing cardiac surgery and expected to be high risk

Exclusion Criteria:

* preoperative extracorporeal organ support
* CKD history (GFR\<60ml/min/1.73m2 \[≤1year\] and GFR\<90ml/min/1.73m2 \[\>1 year\])
* serum creatinine defined preoperative AKI.

Primary outcomes:
measure: Number of Participants with Amino acids Related Adverse Events
timeFrame: Baseline, Daily during infusion upto 48 hours after completion of infusion (upto 5 days)
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Lucile Packard Children's Hospital
state: California
Study officials:
affiliation: Stanford University
name: Shina Menon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02367898: Enhancing Cognitive Abilities With Comprehensive Training
Official title: Enhancing Cognitive Abilities With Comprehensive Training: A Large, Online, Randomized, Active-Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognitive Abilities
Keywords: Cognitive Training
Lumosity
Crossword Puzzles
Lead sponsor: Lumos Labs, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Wheaton College
name: Wayne State University
First posted: 2015-02-20
Enrollment: 11470
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to measure the efficacy of an online cognitive training program against an active control condition in a large, randomized trial.

Detailed description: The present study aims to evaluate a targeted, progressively challenging, online cognitive training program comprised of 49 distinct exercises targeting a variety of cognitive capacities. The cognitive training program will be compared to a plausibly beneficial active control condition in which participants completed online crossword puzzles.

The investigators hypothesize that the cognitive training will show greater transfer to a range of underlying cognitive abilities than the active control, as measured by a broad battery of neuropsychological assessments and participant-reported outcomes.

Eligibility criteria: Inclusion Criteria:

* Engaged with the Lumosity program at least 3 days in the first week after sign-up
* Access to an internet enabled computer to complete training

Exclusion Criteria:

* Paying subscriber

Primary outcomes:
measure: Aggregate Cognitive Performance
timeFrame: Baseline to 10 weeks
Secondary outcomes:
measure: Participant-Reported Outcomes
timeFrame: Baseline to 10 weeks
measure: Individual Neuropsychological Assessments composite
timeFrame: Baseline to 10 weeks
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Lumos Labs, Inc.
state: California
Study officials:
affiliation: Lumos Labs, Inc.
name: Daniel Sternberg, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hardy JL, Nelson RA, Thomason ME, Sternberg DA, Katovich K, Farzin F, Scanlon M. Enhancing Cognitive Abilities with Comprehensive Training: A Large, Online, Randomized, Active-Controlled Trial. PLoS One. 2015 Sep 2;10(9):e0134467. doi: 10.1371/journal.pone.0134467. eCollection 2015.